FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 210 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective October 24, 2023 Reunión anual de la American Society of Clinical Oncology de 2022:... June 5, 2022 Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer March 27, 2019 How and When to Wash Your Reusable Cloth Mask and When... November 30, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Crisantaspase Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... 2023 ASCO Annual Meeting Research Round Up: Progress in Preventing Melanoma... 5 ways cancer can impact sexual wellbeing
